Goldman Sachs
DOVA

Goldman Sachs’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Goldman Sachs’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-255,362
Closed -$7.14M – 5546
2019
Q3 		$7.14M Buy
255,362
+237,523
+1,331% +$3.85M ﹤0.01% 2588
2019
Q2 		$252K Sell
17,839
-3,695
-17% -$35.1K ﹤0.01% 4689
2019
Q1 		$191K Buy
21,534
+4,902
+29% +$39.8K ﹤0.01% 4814
2018
Q4 		$126K Sell
16,632
-2,943
-15% -$47.4K ﹤0.01% 4956
2018
Q3 		$410K Buy
19,575
+2,329
+14% +$55.5K ﹤0.01% 4523
2018
Q2 		$516K Buy
17,246
+1,703
+11% +$46.4K ﹤0.01% 4491
2018
Q1 		$422K Sell
15,543
-466
-3% -$13.9K ﹤0.01% 4584
2017
Q4 		$461K Buy
+16,009
New +$439K ﹤0.01% 4884
2017
Q3 		– Sell
-22,100
Closed -$493K – 6993
2017
Q2 		$493K Buy
+22,100
New +$465K ﹤0.01% 5109

Goldman Sachs's DOVA Position: Q4 2019 in Review

Goldman Sachs sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 255,362 shares — an estimated $7.14M sold.

Goldman Sachs first reported a position in DOVA in Q2 2017 and held it in 9 quarters. The position peaked at $7.14M in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • Goldman Sachs reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 255,362 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $7.14M.
  • Goldman Sachs first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
  • Goldman Sachs's Dova Pharmaceuticals, Inc. Common Stock position peaked at $7.14M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.